Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METHAZOLAMIDE vs ACETAZOLAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.
Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.
FDA: Adjunctive treatment of open-angle glaucoma or secondary glaucoma; preoperative treatment of acute angle-closure glaucoma.,Off-label: Management of idiopathic intracranial hypertension (pseudotumor cerebri); metabolic alkalosis; acute mountain sickness.
Edema due to congestive heart failure (adjunctive therapy),Drug-induced edema,Centrencephalic epilepsies (petit mal, unlocalized seizures),Chronic simple (open-angle) glaucoma,Secondary glaucoma,Preoperative lowering of intraocular pressure in acute angle-closure glaucoma,Altitude sickness (prevention and treatment),Off-label: Idiopathic intracranial hypertension, metabolic alkalosis, sleep apnea, bipolar disorder, cystinuria, hypokalemic periodic paralysis
Oral: 50-100 mg two to three times daily.
250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.
Terminal half-life: 14-20 hours; approximately 15 hours in adults, prolonged in renal impairment
Terminal half-life approximately 10–15 hours; prolonged in renal impairment (up to 30+ hours).
Hepatic metabolism via CYP3A4; metabolites include N-demethylated and S-oxidized products.
Primarily excreted unchanged in urine (70-100%). Minor metabolism via hydrolysis of acetyl group (possibly by plasma esterases) to acetazolamide, and glucuronide conjugation.
Renal: 70-90% as unchanged drug; minor biliary/fecal (<10%)
Renal: ~90% unchanged drug via tubular secretion and glomerular filtration; minor biliary/fecal (<2%).
~95% bound to plasma proteins (primarily albumin)
~70–90% bound primarily to carbonic anhydrase in erythrocytes and plasma proteins (albumin).
0.2-0.3 L/kg; indicates distribution primarily in extracellular fluid
0.2–0.3 L/kg; concentrates in tissues with high carbonic anhydrase content (RBCs, kidneys, eyes).
Oral: ~90% (well absorbed); IM: not typically used; IV: 100%
Oral: ~100% (well absorbed); IV: 100%.
GFR 10-50 m L/min: Administer every 12 hours; GFR <10 m L/min: Not recommended.
Cr Cl 10-50 m L/min: administer every 12 hours; Cr Cl <10 m L/min: avoid use (ineffective).
No specific guidelines; use with caution in severe hepatic impairment.
Child-Pugh class A: no adjustment; Child-Pugh class B-C: caution, reduce dose by 50% and monitor for encephalopathy.
Oral: 5-10 mg/kg/day divided every 6-8 hours; maximum 30 mg/kg/day.
Children: 5-10 mg/kg/dose orally or IV every 8-12 hours; maximum 500 mg/dose.
Initiate at low end of dosing range due to age-related renal function decline; monitor electrolytes and renal function.
Initiate at lowest effective dose (250 mg daily) due to increased risk of electrolyte disturbances and renal impairment.
None.
WARNING: Metabolically induced acidosis. Use with caution in patients with hepatic cirrhosis to avoid precipitation of hepatic encephalopathy. Not recommended for long-term use in patients with chronic noncongestive angle-closure glaucoma due to risk of increased intraocular pressure with lens displacement.
Sulfonamide hypersensitivity reactions; metabolic acidosis; electrolyte disturbances (hypokalemia); drowsiness and confusion; potentiation of acidosis in renal impairment; risk of nephrolithiasis; caution with concomitant use of high-dose aspirin (risk of toxicity).
Sulfonamide hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) - discontinue at first sign of rash,Metabolic acidosis - monitor electrolytes, use with caution in patients with respiratory acidosis or those at risk,Hepatic impairment - contraindicated in cirrhosis; may precipitate hepatic encephalopathy,Renal impairment (Cr Cl <10 m L/min) - ineffective and may cause metabolic acidosis,Hematologic reactions (agranulocytosis, aplastic anemia) - monitor CBC,Hypercalciuria and renal stone formation - ensure adequate hydration,Drowsiness, confusion, fatigue - impaired ability to drive/operate machinery,Use in pregnancy - potential risk; cross-sensitivity with sulfonamides
Hyponatremia or hypokalemia; severe renal or hepatic impairment; adrenal insufficiency; hypersensitivity to sulfonamides or thiazide diuretics; concurrent use with high-dose aspirin.
Hypersensitivity to acetazolamide or any sulfonamide derivative,Severe hepatic cirrhosis or hepatic impairment,Severe renal impairment (Cr Cl <10 m L/min) or anuria,Hyponatremia or hypokalemia,Adrenocortical insufficiency (Addison's disease),Long-term use in chronic noncongestive angle-closure glaucoma,Metabolic acidosis
No specific food interactions. Maintain adequate hydration. Avoid excessive intake of sodium bicarbonate or antacids containing bicarbonate.
Avoid high doses of vitamin C or cranberry juice as they may acidify urine and decrease drug effectiveness. Maintain adequate hydration; no specific food restrictions.
First trimester: Crosses placenta; based on animal studies, may cause skeletal and soft tissue malformations. Human data limited but caution advised. Second and third trimesters: Risk of fetal acidosis and electrolyte disturbances due to carbonic anhydrase inhibition. Avoid if possible.
First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause fetal metabolic acidosis, electrolyte disturbances, and growth retardation.
Methazolamide is excreted into breast milk; M/P ratio not established. Potential for metabolic acidosis or sulfonamide-related adverse effects in nursing infant. Use only if benefit outweighs risk; consider alternative agents.
Excreted into breast milk (M/P ratio approximately 0.25). Not recommended due to risk of sulfonamide-related adverse effects (e.g., kernicterus in jaundiced infants, hemolytic anemia in G6PD deficiency).
No pharmacokinetic studies in pregnancy; increased glomerular filtration rate may reduce serum levels. Empirical dose adjustment not recommended; monitor clinical effect and adjust as needed.
No standard dose adjustment recommended; pharmacokinetics altered (increased Vd, decreased Cmax) but clinical significance uncertain. Monitor for metabolic acidosis and adjust if necessary.
Methazolamide is a carbonic anhydrase inhibitor used for glaucoma. Monitor serum electrolytes, especially potassium, as hypokalemia is common. Contraindicated in patients with hepatic cirrhosis due to risk of hepatic encephalopathy. Avoid in patients with adrenal insufficiency. Adjust dose in renal impairment. Use with caution in patients with pulmonary obstruction or emphysema as it can cause metabolic acidosis.
Acetazolamide is a carbonic anhydrase inhibitor used for glaucoma, altitude sickness, and as a diuretic. Monitor serum electrolytes (especially potassium and bicarbonate) due to metabolic acidosis risk. Avoid in severe hepatic or renal impairment. Can cause paresthesias, especially in hands and feet. Use with caution in patients with sulfonamide allergy as cross-reactivity is possible but rare.
Take this medication exactly as prescribed, usually twice a day.,You may experience tingling in the fingers or toes, which is common and usually harmless.,Drink plenty of fluids to prevent kidney stones.,Avoid alcohol as it may increase side effects.,Report any signs of infection, easy bruising, or bleeding.,Do not drive or operate heavy machinery until you know how this medication affects you.,This medication may cause sensitivity to sunlight; use sunscreen and protective clothing.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double dose.
Take exactly as prescribed; do not stop suddenly.,May cause tingling or numbness in fingers, toes, or mouth; this is usually temporary.,Drink plenty of fluids unless otherwise directed; avoid excessive alcohol.,Report unusual fatigue, muscle cramps, or rapid breathing to your doctor.,Avoid prolonged sun exposure; use sunscreen as photosensitivity may occur.,If used for altitude sickness, start 1-2 days before ascent and continue during climb.
"The combination of Triamterene, a potassium-sparing diuretic that inhibits epithelial sodium channels in the distal nephron, with Methazolamide, a carbonic anhydrase inhibitor that reduces renal bicarbonate reabsorption, can lead to severe hyperkalemia and metabolic acidosis due to additive effects on renal electrolyte handling. Both drugs impair renal potassium secretion, while Methazolamide-induced metabolic acidosis further exacerbates hyperkalemia by shifting potassium extracellularly. This synergistic disruption of acid-base balance and potassium homeostasis significantly increases the risk of life-threatening cardiac arrhythmias and neurological impairment."
"Carteolol, a non-selective beta-blocker, can blunt the compensatory sympathetic response to metabolic acidosis induced by methazolamide, a carbonic anhydrase inhibitor. This can lead to excessive bradycardia, hypotension, and potentially precipitate heart failure. The additive effects on lowering intraocular pressure may also be affected."
"Phentermine, a sympathomimetic amine, may competitively inhibit the renal tubular secretion of methazolamide, a carbonic anhydrase inhibitor primarily eliminated via active tubular secretion. This can lead to reduced clearance and increased systemic exposure of methazolamide, potentially elevating its serum levels and prolonging its therapeutic and adverse effects such as metabolic acidosis, paresthesias, and electrolyte imbalances. Clinical outcomes may include increased risk of methazolamide toxicity, particularly in patients with renal impairment, and enhanced diuretic or ocular hypotensive effects."
"Bosutinib, a potent CYP3A4 inhibitor, can significantly increase the serum concentration of acetazolamide, a carbonic anhydrase inhibitor, by reducing its hepatic metabolism. This elevation may potentiate acetazolamide's adverse effects, including metabolic acidosis, electrolyte imbalances (e.g., hypokalemia), and paresthesias, especially in patients with renal impairment. Clinicians should monitor for signs of acetazolamide toxicity when coadministered with bosutinib."
"Acetazolamide, a carbonic anhydrase inhibitor, can cause metabolic acidosis and decrease renal tubular secretion of metformin, potentially increasing metformin plasma concentrations. This combination may elevate the risk of lactic acidosis, a rare but serious adverse effect of metformin. Additionally, acetazolamide-induced hypokalemia can exacerbate metformin-associated hyperlactatemia."
"Acetazolamide, a carbonic anhydrase inhibitor, increases urinary pH and promotes bicarbonate excretion, leading to metabolic alkalosis. This systemic alkalinization enhances renal tubular reabsorption of lithium, paradoxically decreasing lithium clearance and increasing serum lithium concentrations. Clinically, this can precipitate lithium toxicity, manifesting as nausea, tremor, ataxia, or confusion, particularly in patients on stable lithium regimens."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METHAZOLAMIDE vs ACETAZOLAMIDE, answered by our medical review team.
METHAZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Carbonic anhydrase inhibitor; reduces aqueous humor secretion by inhibiting carbonic anhydrase in ciliary processes, decreasing intraocular pressure.. ACETAZOLAMIDE is a Carbonic Anhydrase Inhibitor that works by Reversible inhibition of carbonic anhydrase, primarily in the proximal renal tubule, reducing hydrogen ion secretion and increasing bicarbonate, sodium, potassium, and water excretion. Also reduces aqueous humor formation via ocular carbonic anhydrase inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METHAZOLAMIDE and ACETAZOLAMIDE depend on the specific clinical indication. These are both Carbonic Anhydrase Inhibitor agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METHAZOLAMIDE is: Oral: 50-100 mg two to three times daily.. The standard adult dose of ACETAZOLAMIDE is: 250-500 mg orally twice daily or 250 mg intravenously twice daily; for edema, 250-375 mg orally once daily; for altitude sickness, 250 mg orally every 8-12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining METHAZOLAMIDE and ACETAZOLAMIDE. The combination of Methazolamide and Acetazolamide, both carbonic anhydrase inhibitors, leads to additive pharmacological effects, resulting in an increased risk of metabolic acidosis, electrolyte imbalances (particularly hypokalemia), and central nervous system depression. This interaction can precipitate severe symptoms such as confusion, lethargy, and respiratory compensation failure, especially in patients with renal impairment or concurrent diuretic use. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. METHAZOLAMIDE is classified as Category C. First trimester: Crosses placenta; based on animal studies, may cause skeletal and soft tissue malformations. Human data limited but caution advised. Second and third trimesters: R. ACETAZOLAMIDE is classified as Category C. First trimester: Avoid; associated with increased risk of congenital malformations (limb defects, hypospadias). Second and third trimesters: Use only if clearly needed; may cause f. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.